Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John W Frew

Showing results (51-60 of 91) with videos related to

Pageof 10
Sort By:
The Journal of Allergy and Clinical Immunology|February 6, 2021
Epithelialized tunnels are a source of inflammation in hidradenitis suppurativaKristina Navrazhina, John W Frew, Patricia Gilleaudeau, et al.
JAAD International|August 19, 2021
Quantifying the natural variation in lesion counts over time in untreated hidradenitis suppurativa: Implications for outcome measures and trial designJohn W Frew, Caroline S Jiang, Neha Singh, et al.
The Australasian Journal of Dermatology|March 10, 2026
Efficacy of Biologics for Hidradenitis Suppurativa: A Network Meta Analysis and Meta Regression for Baseline Disease SeverityJames Pham, Tara Sholji, Marra Aghajani, et al.
The Journal of Allergy and Clinical Immunology|June 3, 2021
High inflammation in hidradenitis suppurativa extends to perilesional skin and can be subdivided by lipocalin-2 expressionKristina Navrazhina, Sandra Garcet, Xiuzhong Zheng, et al.
The Journal of Investigative Dermatology|November 15, 2024
The Clinical and Molecular Response of Pyoderma Gangrenosum to IL-23 Blockade: Result from a Proof-of-Concept Open-Label Clinical TrialAkshay Flora, James Pham, Jane A Woods, et al.
JAMA Dermatology|May 8, 2024
Economic Evaluation of HLA-B*15:02 Genotyping for Asian Australian Patients With EpilepsyYaron Gu, Sophy T F Shih, Nimeshan Geevasinga, et al.
Journal of the American Academy of Dermatology|December 28, 2019
Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient dataJohn W Frew, Caroline S Jiang, Neha Singh, et al.
Journal of the American Academy of Dermatology|August 2, 2021
The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgarisKristina Navrazhina, Sandra Garcet, John W Frew, et al.
The Journal of Investigative Dermatology|September 13, 2020
A Systematic Review of Promising Therapeutic Targets in Hidradenitis Suppurativa: A Critical Evaluation of Mechanistic and Clinical RelevanceJohn W Frew, Angelo V Marzano, Kerstin Wolk, et al.
Journal of the American Academy of Dermatology|May 17, 2020
The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort studyJohn W Frew, Kristina Navrazhina, David Grand, et al.
Pageof 10

Showing results (51-60 of 91) with videos related to

Sort By:
Pageof 10
The Journal of Allergy and Clinical Immunology|February 6, 2021
Epithelialized tunnels are a source of inflammation in hidradenitis suppurativaKristina Navrazhina, John W Frew, Patricia Gilleaudeau, et al.
JAAD International|August 19, 2021
Quantifying the natural variation in lesion counts over time in untreated hidradenitis suppurativa: Implications for outcome measures and trial designJohn W Frew, Caroline S Jiang, Neha Singh, et al.
The Australasian Journal of Dermatology|March 10, 2026
Efficacy of Biologics for Hidradenitis Suppurativa: A Network Meta Analysis and Meta Regression for Baseline Disease SeverityJames Pham, Tara Sholji, Marra Aghajani, et al.
The Journal of Allergy and Clinical Immunology|June 3, 2021
High inflammation in hidradenitis suppurativa extends to perilesional skin and can be subdivided by lipocalin-2 expressionKristina Navrazhina, Sandra Garcet, Xiuzhong Zheng, et al.
The Journal of Investigative Dermatology|November 15, 2024
The Clinical and Molecular Response of Pyoderma Gangrenosum to IL-23 Blockade: Result from a Proof-of-Concept Open-Label Clinical TrialAkshay Flora, James Pham, Jane A Woods, et al.
JAMA Dermatology|May 8, 2024
Economic Evaluation of HLA-B*15:02 Genotyping for Asian Australian Patients With EpilepsyYaron Gu, Sophy T F Shih, Nimeshan Geevasinga, et al.
Journal of the American Academy of Dermatology|December 28, 2019
Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient dataJohn W Frew, Caroline S Jiang, Neha Singh, et al.
Journal of the American Academy of Dermatology|August 2, 2021
The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgarisKristina Navrazhina, Sandra Garcet, John W Frew, et al.
The Journal of Investigative Dermatology|September 13, 2020
A Systematic Review of Promising Therapeutic Targets in Hidradenitis Suppurativa: A Critical Evaluation of Mechanistic and Clinical RelevanceJohn W Frew, Angelo V Marzano, Kerstin Wolk, et al.
Journal of the American Academy of Dermatology|May 17, 2020
The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort studyJohn W Frew, Kristina Navrazhina, David Grand, et al.
Pageof 10